Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Motexafin Gadolinium, Temozolomide, and Radiation in Newly Diagnosed Glioblastoma
NCT00305864Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Feb 2006
- Primary completion
- Feb 2011
- Modality
- Orthosteric Ligands, Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label trial of motexafin gadolinium in glioblastoma multiforme (GBM) and Gliosarcoma (GS) (4 arms), sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose at 90 days and Overall Survival at 54.3 months. Started Feb 2006; status: completed.
02
Drugs
motexafin gadolinium
03
Conditions
glioblastoma multiforme (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on NCT00305864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00305864.